Anthem Biosciences (ANTHEM) Fundamentals 2026 — P/E 73.9x, Revenue Analysis | SniperIQ
Anthem Biosciences (ANTHEM) is a India-listed Healthcare company in Biotechnology with a market capitalization of ₹43,752 Crore, trading at ₹778.90 on the NSE. This SniperIQ fundamentals page covers Anthem Biosciences's valuation (P/E 73.9x, P/B 14.4x), profitability (net margin 27.9%), revenue (₹2,124 Crore in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Anthem Biosciences's market cap?
Anthem Biosciences (ANTHEM) has a market capitalization of approximately ₹43,752 Crore, trading at ₹778.90 on the NSE. Market cap moves with the live share price.
What is Anthem Biosciences's P/E ratio?
Anthem Biosciences's trailing twelve-month P/E ratio is 73.9x, with a price-to-book (P/B) of 14.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Anthem Biosciences?
Anthem Biosciences runs a net profit margin of 27.9%, a gross margin of 46.9%, and an operating margin of 32.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Anthem Biosciences generate?
Anthem Biosciences reported revenue of ₹2,124 Crore for fiscal year 2025, with net income of ₹592 Crore and earnings per share (EPS) of 10.55. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Anthem Biosciences pay a dividend?
Anthem Biosciences offers a trailing dividend yield of about 0.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Anthem Biosciences financially healthy?
Anthem Biosciences carries a debt-to-equity ratio of 0.02x and a current ratio of 5.54x, with a market beta of 0.53. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Anthem Biosciences a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Anthem Biosciences (ANTHEM) the key facts are: market cap ₹43,752 Crore, P/E 73.9x, revenue ₹2,124 Crore, 52-week range 579.15-873.5. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Anthem Biosciences's full fundamentals live
Get Anthem Biosciences's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.